Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Ainos Inc. (AIMDW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: AIMDW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -92.52% | Avg. Invested days 16 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2.22 | 52 Weeks Range 0.03 - 0.31 | Updated Date 06/26/2025 |
52 Weeks Range 0.03 - 0.31 | Updated Date 06/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2978.02% |
Management Effectiveness
Return on Assets (TTM) -30.93% | Return on Equity (TTM) -82.87% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 9206027 |
Shares Outstanding - | Shares Floating 9206027 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Ainos Inc.
Company Overview
History and Background
Ainos, Inc. (formerly known as SG Blocks, Inc.) was initially focused on using prefabricated modules for construction. It has since transitioned to the biotechnology sector, focusing on developing antiviral and immune-modulating therapies.
Core Business Areas
- Biotechnology: Developing antiviral and immune-modulating therapeutics and medical devices.
Leadership and Structure
The company is led by its executive team, including the CEO and other key management personnel. The organizational structure reflects a focus on research and development, clinical trials, and regulatory affairs within the biotechnology industry.
Top Products and Market Share
Key Offerings
- Veldona: Veldona is Ainos's lead investigational product, an oral interferon alpha formulation designed to treat various viral infections and modulate the immune system. It is currently in clinical development. Market share information is not currently available. Competitors include companies developing similar antiviral therapies, such as Gilead Sciences (GILD) with its antiviral treatments.
- Low-dose Interferon Platform: Ainos has a platform technology based on low-dose interferon alpha, which it is exploring for various therapeutic applications. Market share information is not currently available. Competitors include companies developing interferon-based therapies.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. There is a growing demand for novel antiviral and immune-modulating therapies.
Positioning
Ainos is a relatively small player in the biotechnology industry, focused on developing its interferon alpha platform. Its success depends on the clinical trial outcomes and regulatory approvals of its lead candidate, Veldona.
Total Addressable Market (TAM)
The TAM for antiviral and immune-modulating therapies is substantial, potentially reaching billions of dollars. Ainos's position within the TAM is dependent on the successful development and commercialization of its products.
Upturn SWOT Analysis
Strengths
- Novel low-dose interferon alpha platform
- Focus on antiviral and immune-modulating therapies
- Potential for oral interferon delivery
Weaknesses
- Limited financial resources
- Small market capitalization
- Dependence on successful clinical trial outcomes
- High regulatory risk
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical trial results
- Market demand for new antiviral therapies
Threats
- Competition from established pharmaceutical companies
- Failure in clinical trials
- Regulatory hurdles
- Patent disputes
- Economic downturn
Competitors and Market Share
Key Competitors
- GILD
- MRNA
- PFE
Competitive Landscape
Ainos faces significant competition from larger, more established pharmaceutical and biotechnology companies. Its success depends on differentiating its technology and securing partnerships.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is difficult to analyze due to the company's transition from construction to biotechnology.
Future Projections: Future growth depends on successful clinical trials and regulatory approvals.
Recent Initiatives: Focusing on the clinical development of Veldona and expanding its low-dose interferon alpha platform.
Summary
Ainos Inc. is a high-risk, high-reward biotechnology company focused on developing antiviral and immune-modulating therapies. Its future success depends on the clinical development and regulatory approval of its lead candidate, Veldona. The company faces significant competition and has limited financial resources, requiring strategic partnerships. Overall, Ainos has strong potential but will face numerous challenges to achieve its long-term goals.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ainos Inc.
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2022-08-09 | CEO, President & Chairman of the Board Mr. Chun-Hsien Tsai | ||
Sector Healthcare | Industry Medical Devices | Full time employees 44 | Website https://www.ainos.com |
Full time employees 44 | Website https://www.ainos.com | ||
Ainos, Inc., a dual-platform AI and biotech company, focusing SmellTech, AI diagnostics, and immune therapeutics. Its AI Nose platform uses a smell language model to digitize scent into Smell IDs and turning invisible chemical signals into machine-readable data. The company is also giving AI for robotics, smart factories, senior care, and women's health. In addition, it develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases, plus applications in animal health. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.